InvestorsHub Logo
Followers 33
Posts 3741
Boards Moderated 0
Alias Born 11/17/2011

Re: bobby1151 post# 114679

Friday, 10/20/2017 1:10:49 PM

Friday, October 20, 2017 1:10:49 PM

Post# of 329164
Bobby you're absolutely correct and FDA general clearance would have been approved (with 3 body parts clinical trials completed) if BIEL would have done the 3 trials. They did two clinical trials and relied on the "eye patch" as a 3rd. or the Allay patch as the 3rd. FDA didn't go for it. So knowing that new info, BIEL should have immediately got r done with a back study beginning in Feb 2017. Instead we shareholders got the shaft once again and this fine CEO waited until October to begin the trial...should only take 4 weeks and maybe another 2 weeks to compile data. So MAYBE by Christmas we MIGHT get FDA approval. The FDA WANTS to approve Actipatch for General Clearance...they just need some data because the big pharma players will eat their lunch if they approve without back study...that is the creme de la creme of the pain world.
This CEO knew this or should have known this but he once again went the cheapie route. Probably spent all of our hard earned dollars on God knows what and just now got the $100k-$200k to do the study with the in-house Phd family doctors...maybe it was more or maybe less $$$ than that.
I'm confident the FDA general clearance is coming...Geez I almost said the "S" word, SOON! LOL...but it really is. I guess we just need more Patience!
It's kinda funny when you think about it...WE shareholders need more "Patience", but the CEO is given all the time he desires...hardly ever held accountable for his reckless decisions for the past decade.
So many FDA meetings and he tried to skate another one through...but it didn't work. It truly shows his incompetence, complete lack of understanding and total disregard for shareholder value. Not even the slightest apology to the shareholder for not achieving FDA General Clearance in Feb 2017 when it was fully in his old tired hands.